| abstract |
The present invention provides a diarylhydantoin compound as an androgen receptor modulator. The present invention provides a series of compounds that have potent antagonistic activity and minimal agonist activity against the androgen receptor (AR). These compounds inhibit the growth of hormone refractory prostate cancer. The invention relates to R3 being selected from the group consisting of hydrogen, cyano, formyl, wherein R1 and R2 together contain up to 8 carbon atoms, together with alkyl-substituted alkyl and the carbon to which they are attached, cycloalkyl Or a diarylhydantoin compound selected from the group consisting of substituted cycloalkyl groups, methods of synthesizing it, and methods of using it in the treatment of hormone refractory prostate cancer. [Selection figure] None |